ClinicalTrials.gg
RecruitingNCT06068608Updated Jul 11, 2024

A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy

A Phase 1 interventional study of TNM005 and Placebo in Varicella, sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.
Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this clinical trial is to evaluate the safety and tolerability of TNM005 following a single dose by intramuscular (IM) administration in healthy adult subjects The main questions it aims to answer are:1. safety profile;2. PK properties 3. PD properties

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single ascending dose, phase 1 study designed to evaluate the safety, tolerability, PK, PD (anti-VZV antibody level), and immunogenicity of TNM005, as well as to characterize the PD of VARIZIG, in healthy adult volunteers.

The study also includes a cohort in which eight subjects will receive a single dose of VARIZIG 625 IU. This cohort will be conducted in an open-label fashion and may be initiated as early as the first TNM005 cohort is dosed.

The study include periods of Screening (up to 28 days), in-patient (treatment on Day 1), and safety follow-up until Day 120.

02

Conditions studied

  • Varicella

Browse trials for

03

In context

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

This study's planned enrollment of 48 is below the median of 475 across 149 interventional studies indexed under Chickenpox.

Browse Chickenpox studies →

Lead sponsor

Zhuhai Trinomab Pharmaceutical Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Signed and dated written ;
    1. Are willing and able to comply with scheduled visits, blood sampling, laboratory tests, and other study procedures;
    1. Healthy males or females, 18-55 years of age (both inclusive);
    1. (BMI) within 18.5-31.0 kg/m2 (both inclusive) and body weight ≥50.0 kg for males and ≥45.0 kg for females;
    1. Have no abnormality on physical examination, vital signs, 12-lead , and clinical laboratory tests as determined by the Investigator;
    1. Females must be either surgically sterile or under status at Screening or agree to use a highly effective method of from screening until 120 days after IMP dosing. In addition, males who are sexually active and partners of women of must agree to use effective contraception from screening until 120 days after drug administration.

Exclusion criteria

Exclusion Criteria:

    1. History or evidence of any other acute or chronic disease that, in the opinion of the Investigator, may interfere with the evaluation of the safety or immunogenicity of the drug or compromise the safety of the subject;
    1. History of surgery (except minor outpatient surgery) within three months prior to screening or planned surgery during the study;
    1. History of receiving monoclonal antibody, immunoglobulin, or blood products within six months prior to dosing;
    1. Receipt of systemic medications;
    1. Exposure to any within four weeks prior to drug administration;
    1. History of receiving vaccine(s) against zoster;
    1. Use of any other drug, including over-the-counter medications, and herbs, within 14 days prior to the drug administration or five half-lives of the drug, whichever is longer, except for medication in women of (WOCBP), or concomitant medications that are considered necessary for the subject's welfare and unlikely to interfere with the study;
    1. Donated blood >400 mL or significant blood loss equivalent to 400 mL within one month before Screening; or plasma donation within 14 days before Screening; or any plan of blood or blood product donation during the study;
    1. Positive test at a screening of any of the following: surface antigen (HBsAg), (HCV) antibody, or (HIV) antigen/antibody;
    1. Known or suspected history of drug abuse within the past five years or with a positive urine drug test at Screening or on Day -1;
    1. History of significant alcohol abuse within six months prior to screening or any indication of regular use of more than 14 units of alcohol per week or taking a product containing alcohol two days prior to dosing, or having a positive alcohol breath test on Day -1;
    1. Use of ≥five cigarettes or equivalent nicotine-containing product per day on average over three months prior to Screening; or unwilling to refrain from nicotine products during study participation;
    1. History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG-fusion protein;
    1. History of allergic or anaphylactic reaction to blood products (only for VARIZIG cohort);
    1. IgA deficient subjects at risk for reaction (only for VARIZIG cohort);
    1. Subjects at high risk for thrombotic events, including those with a history of venous or arterial thrombosis, atherosclerosis, or multiple cardiovascular risk factors (only for VARIZIG cohort);
    1. Participation in any other clinical studies with chemical or biological drugs or devices within four weeks or five times the half-life of the specific drug/biologics (whichever is longer) before drug administration;
    1. Nursing mothers or pregnant women;
    1. Subjects considered unsuitable for participating in the study in the opinion of the Investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    TNM005 dose level 1/placebo

    TNM005 on dose level 1 /placebo

    Drug: TNM005 · Drug: Placebo

  • Experimental
    TNM005 dose level 2/placebo

    TNM005 on different dose level 2 /placebo

    Drug: TNM005 · Drug: Placebo

  • Experimental
    TNM005 level 3/placebo

    TNM005 on dose level 3 /placebo

    Drug: TNM005 · Drug: Placebo

  • Experimental
    TNM005 dose level 4/placebo

    TNM005 on dose level 4 /placebo

    Drug: TNM005 · Drug: Placebo

  • Experimental
    TNM005 dose level 5/placebo

    TNM005 on dose level 5 /placebo

    Drug: TNM005 · Drug: Placebo

  • Active comparator
    VARIZIG

    VARIZIG 625 IU

    Drug: VariZIG

Interventions

  • DrugTNM005

    single,intramuscular injection

  • DrugPlacebo

    single,intramuscular injection

  • DrugVariZIG

    a single dose of VARIZIG 625 IU,intramuscular injection

06

What researchers measure

Primary outcomes

  1. Incidence of AEs

    Time frame: Up to 120 days post dosing

  2. Number of participants Physical examinations abnormalities

    Physical examination includes assessments of general appearance, skin, lymph nodes, head.neck, lung, heart, abdomen, spine, extremities, nervous system, etc.

    Time frame: Up to 120 days post dosing

  3. Number of participants with abnormalities of vital signs

    Vital signs measured include blood pressure, pulse rate, temperature, and respiration rate.

    Time frame: Up to 120 days post dosing

  4. Number of participants with abnormalities of 12-lead electrocardiogram (ECG) parameters

    ECG parameters include heart rate, PR interval, RR interval, ORS duration, QTcF interval.

    Time frame: Up to 120 days post dosing

  5. Number of participants with abnormalities of clinical laboratory tests

    Clinical laboratory tests include hematology, biochemistry, coagulation, and urinalysis.

    Time frame: Up to 120 days post dosing

Secondary outcomes

  1. AUC0-t

    Area under the plasma concentration-time curve from time 0 (predose) to the last time point with a detectable plasma concentration (Tlast.).

    Time frame: Up to 120 days post dosing

  2. AUC0-∞

    Area under the plasma concentration-time curve from time 0 (predose) extrapolated to infinite time.

    Time frame: Up to 120 days post dosing

  3. Cmax

    Maximum plasma concentration

    Time frame: Up to 120days post dosing

  4. Tmax

    Time to reach maximum plasma concentration

    Time frame: Up to 120 days post dosing

  5. t1/2

    Elimination half-life

    Time frame: Up to 120days post dosing

  6. λz

    Terminal disposition rate constant

    Time frame: Up to 120days post dosing

  7. CL/F

    Apparent clearance

    Time frame: Up to 120days post dosing

  8. Vd/F

    Apparent volume of distribution

    Time frame: Up to 120days post dosing

  9. t1/2 of anti-varicella-zoster virus (VZV) antibody level (both baseline corrected and uncorrected)

    Elimination half-life of antibody level of anti-VZV

    Time frame: Up to 120days post dosing

  10. ADA

    Incidence of anti-drug antibody (ADA) to TNM005 in serum

    Time frame: Up to 120days post dosing

07

Study locations

1 of 1 sites recruiting
  • ICON, plc
    Salt Lake City, Utah 84124, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Dec 2024, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2023
First posted
Oct 5, 2023
StartActual
Sep 12, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06068608
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Sep 12, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 11, 2024

Study contacts

Ying Wang
Contact
emma.wang@trinomab.com
+86 0756 7263999
Miaoyan Chen
Contact
chenmiaoyan@trinomab.com
+86 0756 7263999
Ahad Sabet, MD
principal investigator · ICON plc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion